PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Improved Pegylated-Interferons and Anti-virals Key to Driving Uptake and Increase Treatment Rates - New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of U.S. Hepatitis B and C Markets, reveals that hepatitis markets earned revenue of $ 2,180.0 million in 2005 and estimates to reach $4,778.1 million in 2012.
Improved Pegylated-Interferons and Anti-virals Key to Driving Uptake and Increase Treatment Rates

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2006/02/22 - New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of U.S. Hepatitis B and C Markets, reveals that hepatitis markets earned revenue of $ 2,180.0 million in 2005 and estimates to reach $4,778.1 million in 2012..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

There is a huge unmet need in hepatitis B and C treatments, which has seen problems with the emergence of viral resistance and side effects. The huge potential offered by the market has encouraged companies to build a strong pipeline of therapies.

New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of U.S. Hepatitis B and C Markets, reveals that hepatitis markets earned revenue of $ 2,180.0 million in 2005 and estimates to reach $4,778.1 million in 2012.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the Strategic Analysis of U.S. Hepatitis B and C Markets then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

"Hepatitis B and C markets suffer from the lack of effective treatment options resulting in low treatment rates," notes Frost & Sullivan Research Analyst Barath Shankar.

The existing therapies have side-effects that restraints usage and poses and additional challenge of side-effects and co-infection management.

Large undiagnosed population of hepatitis B and C carriers is growing and the absence of effective treatment options has resulted in low treatment rates. However, newer and effective treatments are likely to be launched, which are expected to aid in an increase in diagnosis and treatment rates.

"The existing therapeutic options are likely to loose their market shares to newer therapies that are expected to be launched," explains Barath Shankar. "The market is likely to grow to be more competitive with more companies expected to enter market."

Pharmaceutical companies need to focus on improving efficacy, manage side-effects and overcome viral resistance that has arisen from older therapeutic options.

Strategic Analysis of U.S. Hepatitis B and C Markets, a part of the pharmaceuticals and biotechnology subscription service, provides an overview and outlook for the market. This study has been segmented as hepatitis B and C markets. This research includes detailed patient, pricing and revenue forecasts, industry trends and market share analysis that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

Strategic Analysis of U.S. Hepatitis B and C Markets

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Improved Pegylated-Interferons and Anti-virals Key to Driving Uptake and Increase Treatment Rates

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Thales Launches the Pixium Portable 3543 DR Wifi Enabled Flat Panel Detector
GE Healthcare Showcases Industry-first Technologies and Digital Solutions, Focused on Improving Outcomes, At RSNA 2016
Agfa and LCsys Team Up to Launch ABSOLUT-ID, Their Turnkey Integrated Solution for the Production of High Security ID Cards
ZOLL Technology for Improving CPR Quality to be Showcased at American Heart Association Annual Conference
AccuVein to Exhibit Leading Vein Visualization Technology at American Society for Dermatologic Surgery Annual Meeting
US Biomedical Textiles Transform Implant Device Technology by Aligning to Changes in Patient Preference Finds Frost & Sullivan
Frost & Sullivan Commends Influence Health for Constantly Evolving its Patient Engagement Products to Accelerate Market Transformation
Frost & Sullivan Awards Carestream Top Honors for OnSight 3D Extremity System
Sparta Systems Launches the Next-Generation Cloud Solution Stratas QMS
Koning Wins Accolades from Frost & Sullivan for the Impressive Innovation Behind its Groundbreaking KBCT Breast Imaging Device
Frost & Sullivan Awards ResMed for Developing S+ Advanced Sleep Tracking System
Sparta Systems Becomes First Quality Management Solutions Provider to Achieve EU-U.S. Privacy Shield Compliance
ZOLL Expands the Rescuer Experience at EMS World Expo
Agfa and GPMI Sign Distribution Agreement for Agfa’s Synthetic Paper Synaps
Frost & Sullivan Highlights iLine Microsystems for Developing a Microfluidics-Based Sophisticated POC Device for PT/INR Coagulation Testing

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)